What This Advancement Means for Equines and Equestrians
Equine medicine has continued to advance in ways that improve quality of life for horses while giving horse owners greater confidence in long term care decisions. A recent milestone is the FDA approval of Dechra’s Zygolide tablets, which expands available options for Equine Cushing’s Disease treatment. This approval is especially meaningful because Equine Cushing’s Disease is one of the most common endocrine disorders affecting older horses.
With Zygolide now approved by the U.S. Food and Drug Administration, managing this chronic condition may become more accessible and consistent for veterinarians and horse owners alike.
Read on to learn more about this new equine medication, how it is used, and why this approval matters.
What Is Zygolide and How Is It Used
Zygolide by Dechra is a veterinarian prescribed pergolide tablet administered orally to help manage the clinical signs associated with pituitary pars intermedia dysfunction, more commonly referred to as Equine Cushing’s Disease. Pergolide based medications are a cornerstone of treatment and are used to help regulate hormone activity affected by the condition.
By supporting hormone regulation, Zygolide can help reduce clinical symptoms and improve overall comfort and quality of life for horses diagnosed with PPID. Dechra describes Zygolide as a first to market generic, peppermint flavored pergolide tablet developed specifically for horses with pituitary pars intermedia dysfunction.
Zygolide became available in January of 2026 following FDA approval and is now accessible to veterinarians through major equine pharmacies across the United States. As with all prescription medications, dosing and treatment plans should be determined by a veterinarian based on each horse’s individual needs and response.
What Is Equine Cushing’s Disease
Equine Cushing’s Disease is an age related endocrine disorder caused by changes in the pituitary gland. These changes are often associated with a benign tumor in the pars intermedia, which disrupts normal hormone regulation. One hormone commonly affected is adrenocorticotropic hormone, which plays a role in immune function, metabolism, and stress response.
It is estimated that Equine Cushing’s Disease affects approximately twenty percent of older horses, making it a common consideration in senior horse health care and Equine Cushing’s Disease treatment planning.
While blood testing is typically required for diagnosis, horse owners may notice several common clinical signs, including:
- Long or curly coat with delayed shedding
- Muscle loss and topline deterioration
- Increased drinking and urination
- Lethargy or reduced energy
- Laminitis
Additional signs may include abnormal sweating, skin changes, unusual fat deposits above the eyes or along the crest and tailhead, and noticeable changes in behavior or attitude. For more on monitoring and supporting your horse’s overall health, see Horse Hoof Care, How to Support Healthy Hooves.
Although Equine Cushing’s Disease is not considered fatal, it does require ongoing management. With appropriate veterinary oversight and consistent treatment, many horses can maintain a comfortable and active quality of life.
Why This Matters for Equine Cushing’s Disease Treatment
The FDA approval of Zygolide represents an encouraging development for the equestrian community and for veterinarians managing long term endocrine conditions. While pergolide medications have been available previously, this approval introduces an additional generic option that may improve accessibility and consistency in Equine Cushing’s Disease treatment.
FDA approval also provides reassurance that the medication has met established standards for safety, quality, and effectiveness, which is especially important when treating a condition that requires lifelong management.
Understanding treatment options and supporting overall health can improve quality of life and confidence in every horse, similar to the behavioral benefits discussed in Desensitizing Your Horse, From Spooky to Steady.
Final Thoughts
This approval marks meaningful progress in the continued effort to support aging horses and manage chronic conditions responsibly. When left untreated, Equine Cushing’s Disease can lead to more serious health complications, but reliable treatment options allow veterinarians and horse owners to take proactive steps in managing the condition.
If you believe your horse may be showing signs of Equine Cushing’s Disease, consult your veterinarian for proper testing, diagnosis, and guidance on treatment options. Zygolide may be considered as part of an appropriate Equine Cushing’s Disease treatment plan when recommended by a veterinary professional.